Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML-Reference-Cited by-同舟云学术

Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML

Published:2007-12-06 Issue:7 Volume:22 Page:1428-1430
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Hasle H,Abrahamsson J,Arola M,Karow A,O'Marcaigh A,Reinhardt D,Webb D K H,van Wering E,Zeller B,Zwaan C M,Vyas P

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2405060.pdf

Reference15 articles.

1. Hasle H, Clemmensen IH, Mikkelsen M . Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000; 355: 165–169.

2. Hasle H . Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol 2001; 2: 429–436.

3. Hitzler JK, Zipursky A . Origins of leukaemia in children with Down syndrome. Nat Rev Cancer 2005; 5: 11–20.

4. Webb DK . Optimizing therapy for myeloid disorders of Down syndrome. Br J Haematol 2005; 131: 3–7.

5. Abildgaard L, Ellebæk E, Gustafsson G, Abrahamsson J, Hovi L, Jonmundsson G et al. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature. Ann Hematol 2006; 85: 275–280.

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Low‐dose cytarabine and hypomethylating agents for Down syndrome with acute myeloid leukemia;Pediatric Blood & Cancer;2024-03-24

2. Down syndrome-associated leukaemias: current evidence and challenges;Therapeutic Advances in Hematology;2024-01

3. Overview and Epidemiology of Pediatric AML;Pediatric Oncology;2024

4. Too many white cells—TAM, JMML, or something else?;Hematology;2023-12-08

5. Advances in molecular characterization of myeloid proliferations associated with Down syndrome;Frontiers in Genetics;2022-08-10